BamSEC and AlphaSense Join Forces
Learn More

Fulcrum Therapeutics Inc. – Material Contracts

NASDAQ: FULC    
Share price (7/22/26): $3.70    
Market cap (7/22/26): $246 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.20
from 10-K 13 pages Fulcrum Therapeutics, Inc. Executive Employment Agreement This Executive Employment Agreement (The “Agreement”) Is Revised as of December 22, 2025 (The “Effective Date”) by and Between Fulcrum Therapeutics, Inc. (The “Company”) and Curt Oltmans (The “Executive”) (The Company and the Executive Each a “Party” and Together the “Parties”)
12/34/56
EX-10.16
from 10-K 3 pages Fulcrum Therapeutics, Inc. Non-Employee Director Compensation Policy Effective January 23, 2026
12/34/56
EX-10.16
from 10-K 3 pages Fulcrum Therapeutics, Inc. Non-Employee Director Compensation Policy Effective January 24, 2025
12/34/56
EX-10.3
from 10-Q 3 pages Certain Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential Amendment No. 2
12/34/56
EX-10.2
from 10-Q 2 pages Third Amendment to Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan
12/34/56
EX-10.1
from 10-Q 130 pages Certain Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential Collaboration and License Agreement by and Between Fulcrum Therapeutics Inc. and Genzyme Corporation Dated May 11, 2024
12/34/56
EX-10.1
from 10-Q 13 pages Fulcrum Therapeutics, Inc. Executive Employment Agreement
12/34/56
EX-10.12
from 10-K 2 pages Second Amendment to Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan
12/34/56
EX-10.2
from 10-Q 15 pages Fulcrum Therapeutics, Inc. Executiveemployment Agreement
12/34/56
EX-10.1
from 10-Q 48 pages Certain Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential License Agreement Between Camp4 Therapeutics Corp. and Fulcrum Therapeutics Inc. License Agreement
12/34/56
EX-10.2
from 10-Q 15 pages Fulcrum Therapeutics, Inc. Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Certain Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential Amendment
12/34/56
EX-10.1
from 10-Q 7 pages Consulting Agreement 1
12/34/56
EX-10
from 10-K 13 pages Employment Agreement
12/34/56
EX-10
from 10-K 12 pages Material contract
12/34/56
EX-10
from 10-K 17 pages Severance Agreement
12/34/56
EX-10
from 10-K 4 pages January 3, 2023 Robert J. Gould Dear Robert: Fulcrum Therapeutics, Inc. (The “Company”) Is Pleased to Extend You a Consulting Role as Interim Chief Executive Officer of the Company (“Interim CEO”), Reporting to the Board of Directors of the Company (The “Board”), Effective January 3, 2023 (The “Effective Date”). the Terms Are as Follows: 1
12/34/56
EX-10
from 10-K 3 pages Fulcrum Therapeutics, Inc. Non-Employee Director Compensation Policy Effective February 3, 2023
12/34/56
EX-10
from 10-K 2 pages First Amendment to Fulcrum Therapeutics, Inc. 2022 Inducement Stock Incentive Plan
12/34/56
EX-10.1
from 8-K 12 pages Employment Agreement
12/34/56